RCT of Tri-Modalities with I-125 Brachy Therapy and EBRT and Short or Long Term Hormone Therapy for High-risk Localized Prostate Cancer - RCT of Tri-Modalities with I-125 Brachy Therapy and EBRT and Short or Long Term Hormone Therapy for High-risk Localized Prostate Cancer (TRIP Study)

Kanazawa University Translational Research Informatices Center0 个研究点目标入组 340 人开始时间: 2010年8月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have active double cancer 2) Patients with poorly controlled hypertension (i.e., diastolic blood pressure>=120 mm Hg) 3) Patients with severe psychiatric disorders 4) Patients with collagen diseases 5) Patients with poorly controlled diabetes 6) Patients with poorly controlled ischemic cardiac disease 7) Patients who had prior surgery for prostate (transurethral prostatectomy, radical prostatectomy, orchiectomy, other surgery for BPH and/or hyperthermia) 8) Patients who had brachytherapy and/or EBRT 9) Patients who are taking steroid drugs (except for ointment) 10) Patients who are taking other antiandrogen for BPH 11) Patients who had CAB for more than 3 months prior to the registration 12) Patients who are judged inappropriate for the clinical trial by doctors

发起方

Kanazawa University Translational Research Informatices Center